Ελληνικό Ινστιτούτο Παστέρ

Mavroeidi P., Mavrofrydi O., Pappa E., Panopoulou M., Papazafiri P., Haralambous S., and Efthimiopoulos S. Oxygen and Glucose Deprivation Alter Synaptic Distribution of Tau Protein: The Role of Phosphorylation. Journal of Alzheimer’s Disease, 60 (2017) 593–604.

Alé A., Bruna J., Calls A., Karamita M., Haralambous S., Probert L., Navarro X., Udina E. Inhibitionofthe neuronal NFκB pathway attenuates bortezomib-induced neuropathy in a mouse model. Neurotoxicology, Jul; 55:58-64.

Kavrochorianou N., Markogiannaki M., and Haralambous S. IFN-β differentially regulates the function of T cell subsets in MS and EAE. Cytokine and Growth Factor Reviews 30:47-54, (invited)

Kavrochorianou N., Evangelidou M., Markogiannaki M., Tovey M., Thyphronitis G. and Haralambous S. IFNAR signaling directly modulates T lymphocytes activity resulting in milder Experimental Autoimmune Encephalomyelitis development. Journal of Leukocyte Biology 99(1): 175-88.

Kavrochorianou N., Markogiannaki M., Malaktari E., Tovey M., Thyphronitis G., Haralambous S. An Unknown T cell-associated protective role of IFN-I in the development of Experimental Autoimmune Encephalomyelitis (EAE). Cytokine 76(1): 95.

Kavrochorianou N., Markogiannaki M., Thyphronitis G., Haralambous S. A beneficial effect of type I interferon signaling in T cells in the early phase of experimental autoimmune encephalomyelitis (EAE). Cytokine 63(3): 276.

Kavrochorianou N., Evangelidou M., Tovey M., Thyphronitis G., Haralambous S. The immunomodulatory effect of type I interferon signaling in T cells during EAE. Cytokine 59(3): 574.

Tseveleki V., Badounas F., Kavrochorianou N., Haralambous S. Testing the effect of grey mullet bottarga as a dietary supplement in the development and progression of hypercholesterolemia in genetically modified mice that model atherosclerosis in humans. 15th International Symposium on Atherosclerosis and Related Risk Factors " organized by the Greek Cardiology and held at the National Research Institute on November 25, 2011.

Kavrochorianou N., Evangelidou M., Tovey M., Thyphronitis G., and Haralambous S. Lymphoid tissue- specific overexpression of IFNAR1 in mice for the evaluation of the role of IFNα/β. Transgenic Research 19 (2): 335

Ioannou K., Samara P.,  Kavrochorianou N., Bega C., Thyphronitis G.,  Haralambous S., Tsitsilonis O. The C-Terminal decapeptide of prothymosinα induces a TH1-Type immune response in vitro and retards tumor growth in vivo. Proceedings of the 8th Joint Conference of the International Cytokine Society and the international Society for Interferon and cytokine research. Cytokine 52 (1-2): 47-50

Kavrochorianou N., Evangelidou M., Tovey M., Thyphronitis G. and Haralambous S.  A transgenic animal model for the investigation of the role of type I interferons in T lymphocyte biology. Cytokine 48(1-2): 47-48.

Mattheolabakis G., Taoufik E., Haralambous S, Roberts ML, Avgoustakis K. In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles. Eur J Pharm  71(2): 190-195.

Quinones P., Kalkonde Y., Estrada CA., Jimenez F., Ramirez R., H. Martinez, Mack M., Reddick L., Maffi S.,  Haralambous S., Probert L., Ahuja K., Ahuja S. Role of Astrocytes and Chemokine Systems in Acute TNF induced Demyelinating Syndrome: CCR2-dependent Signals promote Astrocyte Activation and Survival via NF-B and Akt. Mol. Cell Neurosc. 37(1): 96-109.

Taoufik E., Tseveleki V., Euagelidou M., Emmanouil M., Voulgari-Kokota A., Haralambous S., and Probert L. Positive and negative implications of TNF neutralization for the pathogenesis of multiple sclerosis.  Neurogenerative diseases 5(1): 32-7

Hayer S., Toshidast-Akrad M., Haralambous S. Jahn-Schmid B., Skriner K., Trembleau S., Dumortier H., Pinol-Roma S., Redlich K., Schett G., Muller S., Kollias G., Smolen J. and Steiner G. Aberrant Expression of the Autoantigen Heterogeneous Nuclear Ribonucleoprotein-A2 (RA33) and Spontaneous Formation of Rheumatoid Arthritis-Associated Anti-RA33 Autoantibodies in TNF-α Transgenic Mice. J. Immunology, 175: 8327-8336.

Douni E., Sfikakis P., Haralambous S., Fernandes P., Kollias G. Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols. Arthritis Res Ther.;6(1):R65-R72.

Aidinis V., Plows D., Haralambous S., Armaka M., Papadopoulos P., Kanaki Z., Koczan D., Thiesen J., Kollias G. Functional analysis of an arthritogenic synovial fibroblast. Arthritis Res Ther. 5(3):R140-157.

Hukkanen M., Platts A., Haralambous S., Ainola M., Konttinen T., Kollias G., Polak M. Induction of inducible nitric oxide synthase, argininosuccinate synthase, and GTP cyclohydrolase I in arthritic joints of human tumor necrosis factor-alpha transgenic mice. J Rheumatol. Apr;30(4):652-659.

Redlich K., Hayer S, Maier A., Dunstan R., Tohidast-Akrad M., Lang S., Turk B., Pietschmann P., Woloszczuk W., Haralambous S., Kollias G., Steiner G., Smolen S., Schett G. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. Mar;46(3):785-792.

Schett G., Hayer S., Tohidast-Akrad M., Schmid J., Lang S., Turk B., Kainberger F., Haralambous S., Kollias G., Newby C., Xu Q., Steiner G., Smolen J. Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice. Arthritis Rheum. Dec; 44 (12):2888-2898.

Neurath F., Hildner K., Becker C., Schlaak F., Barbuleskcu K., Germann T., Schmitt E., Schirmacher P.,  Haralambous S.,  Pasparakis M., ZumBuschenfelde M., Kollias G. and. Marker-Hermann E. Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression. Clin. Exp. Immunol. 115 (1): 42-55.

Haralambous S.,  Plows  D. and  G. Kollias. Attenuation  of  transgenic  TNF-triggered arthritis in t ype I IL-1 receptor knockout mice. Eur. Cyt.Network 9 (3): 421-

Kaymakcalan Z.,  Haralambous S.,  Tracey D.,   Kamen R.,   Salfed   J. and   Kollias G. Prevention of Polyarthritis in human TNF transgenic mice by D2E7: A fully human anti-humanTNF monoclonal antibody. Arthritis and Rheum.41(9):390-392 (D2E7 is now in the market known as Humira)

Douni E., Sfikakis P.,  Haralambous S., Kollias G. Effects of Glucocorticoid and Methotrexate administration on the Tg197 TNF-transgenic mouse model of chronic inflammatory polyarthritis. Arthritis and Rheumatism 41(9):100

Neurath M., Fuss I., Pasparakis M., Alexopoulou L.,  Haralambous S. , Meyerzum H. Buschenfelde, Strober W. and Kollias G.. Predominant pathogenic role of tumor necrosis factor α in experimental colitis in mice. Eur. J. Immunol. 27:1743-1750.

Platts M.,  Haralambous S., Hukkanen J., Gross S., Kollias G., Polak M. Inducible nitric oxide synthase and cyclooxygenase are expressed in human-TNFα transgenic mice which develop arthritis spontaneously. J. Pathology 181: A42

Kollias G., Akassoglou K., Alexopoulou L., Douni E., Haralambous S., Hill S., Kassiotis G., Kontoyiannis D., Pasparakis M., Plows D., Probert L. Animal models of TNF-mediated inflammation. J. of Leukocyte Biology  p: 9

Probert L., Akassoglou K., Alexopoulou L., Douni E.,  Haralambous S., Hill S., Kassiotis G., Kontogiannis D., Pasparakis M., Plows D., and Kollias G. Dissection of the pathologies induced by transmembrane and wild type tumour necrosis factor in transgenic mice. Journal of Leucocyte Biology, 59: 518-525.

Haralambous S., Probert L., Mastrangelo M., Kollias G. and Molony L. Adhesion molecule blockade modulates the development of TNF-triggered arthritis in transgenic mice. Eur. Cytokine Netw., 7: 293